Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Further Publications NeurologyFurther Publications Psychiatry

Association of dopamine D_2/3 receptor binding potential measured using PET and [¹¹C]-(+)-PHNO with post-mortem DR_2/3 gene expression in the human brain

Neuroimage.

Komorowski A, Weidenauer A, Murgaš M, Sauerzopf U, Wadsak W, Mitterhauser M, Bauer M, Hacker M, Praschak-Rieder N, Kasper S, Lanzenberger R, Willeit M

doi: 10.1016/j.neuroimage.

Anxiety and DepressionPsychosis and Schizophrenia

Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist

Clin Schizophr Relat Psychoses.

Citrome L

doi: 10.3371/1935-1232-10.2.109.

Psychosis and Schizophrenia

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

Neuroimage Clin

Sauerzopf U, Weidenauer A, Dajic I, Bauer M, Bartova L, Meyer B, Nics L, Philippe C, Pfaff S, Pichler V, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Pezawas L, Praschak-Rieder N, Willeit M

doi: 10.1016/j.nicl.2021.102813

Migraine and HeadachePsychosis and Schizophrenia

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Schizophr Res.

Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Fleischhacker WW, Nasrallah HA

doi: 10.1016/j.schres.2016.06.030.

Psychosis and Schizophrenia

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

J Psychiatr Res.

Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA

doi: 10.1016/j.jpsychires.

Migraine and HeadacheAnxiety and DepressionPsychosis and Schizophrenia

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Lancet.

Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW

doi: 10.1016/

Further Publications NeurologyFurther Publications Psychiatry

Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR

Front Mol Neurosci.

Silberbauer LR, Gryglewski G, Berroterán-Infante N, Rischka L, Vanicek T, Pichler V, Hienert M, Kautzky A, Philippe C, Godbersen GM, Vraka C, James GM, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Hahn A, Lanzenberger R

doi: 10.3389/fnmol.2019.00172.

RECOMMENDED

Anxiety and Depression

Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression

Transl Psychiatry.

Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Hartmann AM, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R

doi: 10.1038/s41398-018-0308-2.

Psychosis and Schizophrenia

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D_2/3 receptor agonist radioligand study

Transl Psychiatry.

Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer BM, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte HH, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M

doi: 10.1038/s41398-019-0681-5.

Related content

Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DR2/3 gene expression in the human brain

Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR

Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study

Association of dopamine D_2/3 receptor binding potential measured using PET and [¹¹C]-(+)-PHNO with post-mortem DR_2/3 gene expression in the human brain

On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D_2/3 receptor agonist radioligand study